|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
PRICE RANGE CHANGE
Trading: SELL @ $0.16
Signal Strength: WEAK
Indicator MUST BE USED in additional to another technical indicator to confirmation for trading entry. Indicator can be applied to the short term timeframe but is only able to give and indication of the strength of the buyers versus sellers at the market close. This bar analysis can provide guidance on the daily battle between sellers and buyers from the companies recent trading.
Impedimed (ASX:IPD)sellers in control. This is the first day of seller commitment for Impedimed adding strength to an downtrend in the first timeframe & highlights the lack of commitment of buyers to carry positions overnight Over the last 12 months there has been 3 trading days with the closing price in the lower part of the range giving a confirmation ratio of 1.1%. Over the last month there has been 1 trading day with the closing price in the lower range giving a confirmation ratio of 20%. Currently this quarter, closing price has spent 3 days in the lower price range compared to 3 days in the upper range giving a ratio of 1x.
Where the closing price fall within the day’s trading range highlights whether are in control.
[Calculations] Close Today Versus Range Today (CTRT):
1) When the closing price is near the high of the day buyers were in control at the close of the trading session;
2) When the closing price is near the low of the day sellers were in control at the close of the trading session;
3) When the closing price is near the middle of the day’s range where neither the buyers or sellers were in control at the close of the trading session;
PROFILE: Impedimed (IPD.AX)
Stock Exchange: ASX
Ticker Codes: | IPD.AX | ASX:IPD |
ImpediMed Limited, together with its subsidiaries, engages in the development, manufacture, and sale of bioimpedance devices and consumables in Australia, North America, Europe, and internationally. The company operates through Medical and Test & Measurement segments. It offers L-Dex U400, a technology that utilizes the characteristics of frequency dependent current flow to quantify changes in extracellular fluid in the patient's limb; and SFB7, a tetra polar bioimpedance spectroscopy device that scans various frequencies for the estimation of body composition in healthy individuals. The company also provides DF50, a single frequency body composition analysis in healthy individuals; and ImpediVET, a bioimpedance spectroscopy technology for use in veterinary applications. Its products are used in a range of applications, such as in the assessment and monitoring of secondary lymphedema, as well as monitoring of body composition and hydration. In addition, the company is involved in the supply of power precision testing and measuring equipment. ImpediMed Limited was founded in 1999 and is headquartered in Pinkenba, Australia.
|OCL Objective Corporation||6.49||10||35,078||0||NEUTRAL|
|HSN Hansen Technologies||3.54||4.4||1,363,425||0||NEUTRAL|
|GTN GTN Resources||0.7||3.7||7,121||0||NEUTRAL|
|PGC Paragon Care||0.45||3.5||206,495||0||NEUTRAL|
|BLX Beacon Lighting||1.23||3.4||22,040||0||NEUTRAL|
|IGL International Goldfields||2.34||3.1||734,472||0||NEUTRAL|
|URF Us Masters Residential Property Fund||0.84||3.1||201,831||0||NEUTRAL|